ZIOPHARM ONCOLOGY INC (ZIOP) Stock Price & Overview
NASDAQ:ZIOP
Current stock price
The current stock price of ZIOP is 0.8657 null. Today ZIOP is down by -0.88%. In the past month the price decreased by -22.01%. In the past year, price decreased by -76.67%.
ZIOP Key Statistics
- Market Cap
- 187.117M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.43
- Dividend Yield
- N/A
ZIOP Stock Performance
ZIOP Stock Chart
ZIOP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ZIOP. When comparing the yearly performance of all stocks, ZIOP is a bad performer in the overall market: 93.41% of all stocks are doing better.
ZIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ZIOP. ZIOP has a bad profitability rating. Also its financial health evaluation is rather negative.
ZIOP Earnings
ZIOP Forecast & Estimates
13 analysts have analysed ZIOP and the average price target is 4 null. This implies a price increase of 361.48% is expected in the next year compared to the current price of 0.8657.
ZIOP Groups
Sector & Classification
ZIOP Financial Highlights
Over the last trailing twelve months ZIOP reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS decreased by -16.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -22543.47% | ||
| ROA | -78.87% | ||
| ROE | N/A | ||
| Debt/Equity | 0.18 |
ZIOP Ownership
ZIOP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.32 | 380.121B | ||
| AMGN | AMGEN INC | 15.37 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.86 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.15 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.44 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.2 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.98 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.27 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZIOP
Company Profile
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2004-08-20. The firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Company Info
IPO: 2004-08-20
ZIOPHARM ONCOLOGY INC
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston MASSACHUSETTS 02129 US
CEO: Heidi Hagen
Employees: 103
Phone: 16172591970.0
ZIOPHARM ONCOLOGY INC / ZIOP FAQ
What does ZIOP do?
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2004-08-20. The firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
What is the stock price of ZIOPHARM ONCOLOGY INC today?
The current stock price of ZIOP is 0.8657 null. The price decreased by -0.88% in the last trading session.
What is the dividend status of ZIOPHARM ONCOLOGY INC?
ZIOP does not pay a dividend.
How is the ChartMill rating for ZIOPHARM ONCOLOGY INC?
ZIOP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is ZIOPHARM ONCOLOGY INC (ZIOP) stock traded?
ZIOP stock is listed on the Nasdaq exchange.
Can you provide the market cap for ZIOPHARM ONCOLOGY INC?
ZIOPHARM ONCOLOGY INC (ZIOP) has a market capitalization of 187.12M null. This makes ZIOP a Micro Cap stock.
When does ZIOPHARM ONCOLOGY INC (ZIOP) report earnings?
ZIOPHARM ONCOLOGY INC (ZIOP) will report earnings on 2022-03-04, after the market close.